Remedent, Inc. (REMI)
OTCMKTS · Delayed Price · Currency is USD
0.0090
-0.0010 (-10.00%)
At close: Jul 14, 2025
Remedent Employees
Remedent had 3 employees as of March 31, 2023. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$16,700
Profits / Employee
-$110,145
Market Cap
173.07K
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 3 | 0 | - |
Mar 31, 2022 | 3 | 0 | - |
Mar 31, 2021 | 3 | 1 | 50.00% |
Mar 31, 2020 | 2 | -5 | -71.43% |
Mar 31, 2019 | 7 | -4 | -36.36% |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
American Oncology Network | 1,914 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
Silence Therapeutics | 116 |
Remedent News
- 4 years ago - Remedent, Inc. Files Form 15 to Suspend SEC Exchange Act Registration and Applies to Qualify for OTC Markets Alternative Reporting Standard for Pink Sheet Companies - GlobeNewsWire